CITIZENS FINANCIAL GROUP INC/RI (CFG): what the price requires

At today's price, CITIZENS FINANCIAL GROUP INC/RI (CFG) is priced for 13.5% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/CFG

Headline

FieldValue
TickerCFG
CompanyCITIZENS FINANCIAL GROUP INC/RI
Current price$70.39/sh
CompositionConsumer Banking 69% / Commercial Banking 31%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Price-to-book1.24x
Return on equity now7.0%

The implied return on book is non-physical at this price-to-book and is suppressed as misleading. The price sits beyond a 12.4% return on equity sustained for 40 years and is not resolvable as a sustainable-ROE point. The rarity read below is the honest signal.

Solve inputs: computed at a 11.7% cost of equity; ROE searched up to the 12.4% ROE ceiling.

Reconcile: at the x-ray's 9.3% required return this reads ~10.5%; the models below use their own rates.

How unusual the bet is: extreme

ReferenceValue
vs own history+3.56σ
cohort percentile (of 119 peers)36
sustained it ~10 years at this level65%
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.42x3expensive
Earnings1.03x2expensive
Relative0.49x3justifies
Growth1.08x3expensive

Families that justify the price: Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.7%); the inversion above states its own rate.

Per-Model Detail (n=11)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$24.132.92xyesTBVPS $41.76 × 0.58x (ROE (TTM) 7.5% / CoE 9.3%, g=4.9% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption), credit 1.38% allowance/loans → ×0.95)
Relative ValuationRelative$58.121.21xyesP/E 11.6x (blended: static sector reference 10x + trailing (TTM) 15x), scenarios: 9.6x / 11.6x / 13.6x (bear / base = reference held flat / bull), EV/EBITDA N/Ax
Simple DDMGrowth$116.290.61xyesDPS $1.84, g=7.5% (sustainable: ROE (TTM) × retention; not the terminal-growth assumption), ke=9.3%
Two-Stage DDMGrowth$65.331.08xyesStage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$49.671.42xyesBV/sh $60.88, ROE (TTM) 7.5%, ke 9.3%
Two-Stage Excess ReturnAsset$44.701.57xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$54.891.28xyesRev $8.5B, growth 9% (input: historical growth; tapered), Terminal P/S: 3.0x / 3.6x / 4.2x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$143.490.49xyesEPS $4.22, growth 34% (input: historical EPS growth), PEG=0.45 (Undervalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$76.030.93xyes√(22.5 × EPS $4.22 × BVPS $60.88) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$136.170.52xyesEPS $4.22 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$158.250.44xyesEPS $4.22 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$45.621.54xyesEPS $4.22 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (dilution)0.3%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

A bank is worth the return it earns on its capital, so CFG is priced off book value, not an operating multiple. At $67.04 the stock trades near 1.2x book, which prices a return on equity above the elite tier sustained long term, against a recent record that has been improving toward but not yet at that level.

The earnings trajectory is the key fact. Q1 2026 ROTCE reached 12.2%, up from 11.20% for full-year 2025 and 9.81% in 2024, with net interest margin expanding to 3.14% and management guiding to a 16% to 18% ROTCE target by the end of 2027.

The bank trades in the lower half of its peer price-to-book, so the question is whether the ROTCE ramp closes the gap to the price or the price has run ahead of the ramp.

Bull Case

The earnings trajectory is unambiguous and it is the whole bull case. Citizens has been steadily lifting its returns: the 10-K reports ROTCE of 11.20% for 2025 versus 9.81% in 2024, with the efficiency ratio improving to 64.40% from 67.03% and tangible book value per share rising 18% to $38.07, 'driven by a decrease in common shares outstanding of eleven million' (FY2025 10-K, accession 0000759944-26-000028). Q1 2026 carried that momentum further, with ROTCE of 12.2% and net interest margin expanding 7 basis points sequentially to 3.14% on both margin gains and loan growth. The direction of every key bank metric, returns, margin, efficiency, and per-share book value, is up and to the right.

The second leg is the path management has laid out and is hitting. Citizens sees a clear route to a 16% to 18% ROTCE target by the end of 2027, supported by NIM guidance of 3.22% to 3.28% by the fourth quarter of 2026 and 3.30% to 3.50% by the fourth quarter of 2027. The lever behind that is mix shift toward higher-return businesses, most visibly the private bank and wealth unit, which already contributes about 10% of pre-tax income, added $0.11 to EPS in the quarter, and earns an ROE above 25%. Building a high-return private bank inside a regional banking franchise is exactly the kind of structural mix improvement that lifts the blended ROE the entire valuation hinges on.

The third leg is capital and the discount. Citizens returned roughly $500 million to shareholders in Q1 ($198 million in dividends, $300 million in buybacks) and expects to end the second quarter with a CET1 ratio of 10.5% to 10.6%, a comfortable capital position that funds both the buyback and loan growth. Buying back stock while tangible book value per share is compounding double digits is the cleanest accretion a bank can deliver. With the stock in the lower half of its peer price-to-book and the ROTCE climbing toward the peer-leading tier, the bull case is simple: if Citizens reaches its 16% to 18% target, a 1.2x book multiple is far too low, and the gap closes as the returns prove out.

Bear Case

The governance-and-execution question is whether the 16% to 18% ROTCE target is a plan or a promise, because the price is already paying for a good chunk of it. The inversion is blunt: at 1.2x book the market is pricing a sustained return above the elite long-run tier, while the bank has only recently been earning in the low double digits and, on a longer view, closer to 7%. Management has set an ambitious target and is tracking toward it, but bank turnarounds are full of plans that stall when the rate environment or the credit cycle turns. If ROTCE plateaus near 12% rather than reaching 16% to 18%, the price has discounted an outcome that does not arrive, and the lower-half peer multiple turns out to have been fair rather than cheap.

The second risk is the rate and credit sensitivity that drives the whole model. Net interest margin expansion is the engine of the ROTCE ramp, and NIM is a function of the yield curve, deposit competition, and loan demand, none of which Citizens controls. A flattening curve, a deposit-cost war, or weak loan growth would each slow the margin guidance the plan depends on. On the asset side, the 10-K notes the company has been reducing commercial real estate, an acknowledgment of where the risk sits, and a regional bank with consumer and commercial exposure is levered to the credit cycle: a recession that lifts loss provisions would hit earnings directly and stall the ROTCE march. The high-beta nature of the stock (beta well above 1) reflects exactly this cyclicality.

The third issue is capital-return discipline against the cycle. Citizens is buying back stock and paying a dividend while building toward its target, which is fine if the stock is cheap on normalized earnings. But a bank returning capital aggressively must keep enough cushion for a downturn, and the CET1 ratio in the low-10s is solid but not a fortress. If a credit shock arrives mid-plan, the buyback would have to pause, the ROTCE ramp would reverse, and the capital returned at today's prices would look ill-timed. The price is underwriting the 2027 target; the bear simply notes that two years of clean execution through an uncertain rate-and-credit environment is not yet in hand.

Valuation

A bank is valued on the return it earns on its capital, so the relevant frame is price-to-book, not an operating multiple. At $67.04 (June 27, 2026) Citizens trades near 1.2x book, which the inversion reads as pricing a sustained return on equity above the elite 12.5% long-run tier, computed at an 11.8% cost of equity. The reference point that makes this demanding is the gap to the record: the bank has recently been earning in the low double digits and, over a longer horizon, closer to 7%, so the price assumes the ROTCE ramp not only reaches the top tier but holds there. That is a bound, not a solved point, and the model labels it elevated, noting that only about 66% of firms earning this return sustained it for a decade.

The method families bracket a range below the price. Relative valuation lands near $50, the excess-return methods near $45 to $50, the discounted-future-market-cap method near $52, and the two-stage DDM near $65, while the more aggressive dividend and growth-adjusted methods (Simple DDM near $116, Peter Lynch and PEG in the $140s) sit far above because they extrapolate the target ROE forward. The read is coherent: on its current ROTCE of about 12%, the stock looks modestly expensive, with most grounded methods below the price; on its 2027 target of 16% to 18%, it looks cheap, which is what the dividend-discount and growth methods reflect. The valuation is therefore a wager on execution.

Catalysts

The Q1 2026 report was the recent catalyst and it confirmed the trajectory. EPS of $1.13, ROTCE of 12.2%, and net interest margin expansion of 7 basis points sequentially to 3.14% all beat expectations, and profit climbed 39% as NIM and credit improved. Management reiterated the path to a 16% to 18% ROTCE target by the end of 2027 and NIM guidance of 3.22% to 3.28% by 4Q 2026 and 3.30% to 3.50% by 4Q 2027. The private bank and wealth business contributed $0.11 to EPS with an ROE above 25%. The next several quarters are the test of whether NIM keeps expanding toward guidance and whether the private bank keeps scaling, since those are the two levers carrying the ROTCE ramp.

The forward watch items are macro and execution. The rate environment, deposit costs, and loan growth drive the net interest margin that the whole plan depends on, and the credit cycle, particularly in commercial real estate where Citizens has been reducing exposure, is the downside risk to provisions. On capital, the pace of buybacks against a CET1 ratio in the low-10s and the dividend trajectory are the per-share-value levers. For a bank priced for its 2027 target, the catalysts that matter are each quarter of ROTCE progress, continued NIM expansion, private-bank growth, and benign credit; the risk catalysts are a curve flattening, a deposit-cost squeeze, or a credit shock that stalls the ramp.

Sources: Citizens Financial Q1 2026 profit climbs 39% (StockTitan), Citizens Q1 2026 earnings call transcript (Motley Fool), Citizens beats Q1 2026 expectations (Investing.com), Citizens FY2025 10-K.

Peer Cohorts (Per Segment, With Filing Citations)

Consumer Banking (reported)

Commercial Banking (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive CFG report on boothcheck